Drug Trial Radar · NCT07544862
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,000
Planned (sponsor's estimate)
Start
Jun 2, 2026
Primary completion
Dec 2027
Study completion Feb 2028
Sponsor
- Lead sponsor
- Chengdu Kangnuoxing Biopharma,Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
Conditions
- Atopic Dermatitis (AD)
Interventions
StapokibartBiological
subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence rate of adverse reactionsTime frame: From enrollment to the end of treatment at 52 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.